{"id":985709,"date":"2026-07-28T10:28:02","date_gmt":"2026-07-28T14:28:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/"},"modified":"2026-07-28T10:28:02","modified_gmt":"2026-07-28T14:28:02","slug":"rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/","title":{"rendered":"RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY)"},"content":{"rendered":"<p>        <!--.bwalignl { text-align: left }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p>RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY)<\/p>\n<p><i>The investigation focuses on RDY investor losses tied to Dr. Reddy\u2019s FY27 margin guidance after the Company disclosed a \u20b92.4 billion provision connected to out-of-spec semaglutide batches.<\/i><\/p>\n<p>NEW YORK&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;RDY shareholders saw Dr. Reddy\u2019s Laboratories (NYSE: RDY) shares fall approximately 9% on July 22, 2026, after Q1 FY27 results included a \u20b92.4 billion provision tied to out-of-spec semaglutide batches while FY27 margin commentary remained in focus. Investors who lost money on RDY after that provision disclosure are encouraged to act now. Levi &amp; Korsinsky is investigating potential securities law violations involving Dr. Reddy\u2019s forward-looking profitability statements. (212) 363-7500 | <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.zlk.com&amp;esheet=54577823&amp;newsitemid=20260728610600&amp;lan=en-US&amp;anchor=www.zlk.com&amp;index=1&amp;md5=17819dcb543b06dcd90f3553d4679b8b\">www.zlk.com<\/a><\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fzlk.com%2Fcases%2Fdr-reddys-laboratories-limited-class-action-lawsuit-rdy%3Fprid%3D196126%26wire%3D2&amp;esheet=54577823&amp;newsitemid=20260728610600&amp;lan=en-US&amp;anchor=Submit+your+RDY+loss+information.&amp;index=2&amp;md5=12f65c5512ec4db74fa66e4c23c8adf6\">Submit your RDY loss information.<\/a><\/p>\n<p>On May 12, 2026, Chief Executive Officer Erez Israeli stated, \u201cWe remain in the neighbourhood of a 20% EBITDA margin and we expect the margins to improve and be above 50% in FY \u201827.\u201d<\/p>\n<p>The investigation focuses on the Company\u2019s margin outlook and cost commentary surrounding semaglutide. Dr. Reddy\u2019s later disclosed a \u20b92.4 billion provision for out-of-spec semaglutide batches, and on the July 9, 2026 update call, Israeli stated, \u201cnothing has changed besides this event.\u201d<\/p>\n<p>If RDY losses affected your account, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fzlk.com%2Fcases%2Fdr-reddys-laboratories-limited-class-action-lawsuit-rdy%3Fprid%3D196126%26wire%3D2&amp;esheet=54577823&amp;newsitemid=20260728610600&amp;lan=en-US&amp;anchor=send+your+loss+details+now&amp;index=3&amp;md5=556c37c4a1df692da49b72cd9571123a\">send your loss details now<\/a>. You may also call (212) 363-7500.<\/p>\n<p><b>Levi &amp; Korsinsky, LLP<\/b> | Top 50 Securities Firm | (212) 363-7500 | <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.zlk.com&amp;esheet=54577823&amp;newsitemid=20260728610600&amp;lan=en-US&amp;anchor=www.zlk.com&amp;index=4&amp;md5=ca26bac43d81d31b5dbc274e8f7d454e\">www.zlk.com<\/a><\/p>\n<p>Frequently Asked Questions About the RDY Investigation<\/p>\n<p><b>Q: Which statements are being investigated as potentially misleading?<\/b> A: The investigation concerns whether Dr. Reddy\u2019s Laboratories made potentially misleading statements regarding FY27 EBITDA margin expectations, spending levels, and semaglutide-related financial impact before shares fell approximately 9%.<\/p>\n<p><b>Q: Who is eligible to participate in the RDY investigation?<\/b> A: Investors who purchased RDY stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses &#8212; not on whether you still hold the shares.<\/p>\n<p><b>Q: How much did RDY stock drop?<\/b> A: RDY shares fell approximately 9% after Dr. Reddy\u2019s disclosed Q1 FY27 results that included a \u20b92.4 billion provision tied to out-of-spec semaglutide batches.<\/p>\n<p><b>Q: What documents do I need to participate?<\/b> A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.<\/p>\n<p><b>Q: What is a lead plaintiff and why does it matter?<\/b> A: If the investigation proceeds to legal action, a lead plaintiff is the investor a court may appoint to represent affected investors. Lead plaintiffs are typically investors with the largest documented losses. Providing loss information during the investigation phase preserves that option.<\/p>\n<p><b>Q: What if I already sold my RDY shares &#8212; can I still recover losses?<\/b> A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought RDY and sold at a loss may still participate in the investigation.<\/p>\n<p><b>Q: What does it cost me to participate?<\/b> A: There is no upfront cost to participate. Securities investigations are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.<\/p>\n<p><b>Q: Do I need to go to court or give testimony?<\/b> A: No. Participating in the investigation does not require court appearances or depositions. Most affected investors do not appear in court.<\/p>\n<p>Attorney Advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260728610600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260728610600\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260728610600\/en\/<\/a><\/span><\/p>\n<p class=\"bwalignl\">Levi &amp; Korsinsky, LLP<br \/>Joseph E. Levi, Esq.<br \/>Ed Korsinsky, Esq.<br \/>33 Whitehall Street, 27th Floor<br \/>New York, NY 10004<br \/><a rel=\"nofollow\" href=\"mailto:jlevi@levikorsinsky.com\">jlevi@levikorsinsky.com<\/a><br \/>Tel: (212) 363-7500<br \/>Fax: (212) 363-7171<\/p>\n<p><b>KEYWORDS:<\/b> New York United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260728610600\/en\/2742089\/3\/Gradient_%28Square_Mark%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY) The investigation focuses on RDY investor losses tied to Dr. Reddy\u2019s FY27 margin guidance after the Company disclosed a \u20b92.4 billion provision connected to out-of-spec semaglutide batches. NEW YORK&#8211;(BUSINESS WIRE)&#8211;RDY shareholders saw Dr. Reddy\u2019s Laboratories (NYSE: RDY) shares fall approximately 9% on July 22, 2026, after Q1 FY27 results included a \u20b92.4 billion provision tied to out-of-spec semaglutide batches while FY27 margin commentary remained in focus. Investors who lost money on RDY after that provision disclosure are encouraged to act now. Levi &amp; Korsinsky is investigating potential securities law violations involving Dr. Reddy\u2019s forward-looking profitability statements. (212) 363-7500 | www.zlk.com Submit your RDY loss information. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-985709","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY) The investigation focuses on RDY investor losses tied to Dr. Reddy\u2019s FY27 margin guidance after the Company disclosed a \u20b92.4 billion provision connected to out-of-spec semaglutide batches. NEW YORK&#8211;(BUSINESS WIRE)&#8211;RDY shareholders saw Dr. Reddy\u2019s Laboratories (NYSE: RDY) shares fall approximately 9% on July 22, 2026, after Q1 FY27 results included a \u20b92.4 billion provision tied to out-of-spec semaglutide batches while FY27 margin commentary remained in focus. Investors who lost money on RDY after that provision disclosure are encouraged to act now. Levi &amp; Korsinsky is investigating potential securities law violations involving Dr. Reddy\u2019s forward-looking profitability statements. (212) 363-7500 | www.zlk.com Submit your RDY loss information. &hellip; Continue reading &quot;RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-28T14:28:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260728610600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY)\",\"datePublished\":\"2026-07-28T14:28:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\\\/\"},\"wordCount\":605,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260728610600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\\\/\",\"name\":\"RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260728610600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-07-28T14:28:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260728610600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260728610600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/","og_locale":"en_US","og_type":"article","og_title":"RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY) - Market Newsdesk","og_description":"RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY) The investigation focuses on RDY investor losses tied to Dr. Reddy\u2019s FY27 margin guidance after the Company disclosed a \u20b92.4 billion provision connected to out-of-spec semaglutide batches. NEW YORK&#8211;(BUSINESS WIRE)&#8211;RDY shareholders saw Dr. Reddy\u2019s Laboratories (NYSE: RDY) shares fall approximately 9% on July 22, 2026, after Q1 FY27 results included a \u20b92.4 billion provision tied to out-of-spec semaglutide batches while FY27 margin commentary remained in focus. Investors who lost money on RDY after that provision disclosure are encouraged to act now. Levi &amp; Korsinsky is investigating potential securities law violations involving Dr. Reddy\u2019s forward-looking profitability statements. (212) 363-7500 | www.zlk.com Submit your RDY loss information. &hellip; Continue reading \"RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-28T14:28:02+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260728610600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY)","datePublished":"2026-07-28T14:28:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/"},"wordCount":605,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260728610600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/","name":"RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260728610600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-07-28T14:28:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260728610600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260728610600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rdy-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-dr-reddys-laboratories-rdy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"RDY Investor Alert: Levi &amp; Korsinsky Notifies Investors of Investigation Into Dr. Reddy\u2019s Laboratories (RDY)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/985709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=985709"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/985709\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=985709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=985709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=985709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}